NBP Stock - NovaBridge Biosciences
Unlock GoAI Insights for NBP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $4.49M | $-10,697,247 | $88.03M | $1.54B |
| Gross Profit | N/A | $4.49M | $-248,800,000 | $41.59M | $1.54B |
| Gross Margin | N/A | 100.0% | 2325.8% | 47.3% | 100.0% |
| Operating Income | $-375,358,000 | $-511,162,000 | $-366,078,000 | $-2,071,307,000 | $155.57M |
| Net Income | $-162,257,000 | $-1,465,694,000 | $-2,507,317,000 | $-2,331,541,000 | $470.92M |
| Net Margin | N/A | -32674.0% | 23438.9% | -2648.7% | 30.5% |
| EPS | $-4.46 | $-17.62 | $-30.38 | $-30.70 | $8.07 |
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Visit WebsiteEarnings History & Surprises
NBPEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 1, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.04 | — | — | — |
Q4 2025 | Dec 25, 2025 | $-0.06 | — | — | — |
Q3 2025 | Aug 20, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.06 | $-0.04 | +33.3% | ✓ BEAT |
Q2 2025 | Apr 3, 2025 | $-0.01 | $-0.00 | +72.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.16 | $-0.25 | -56.3% | ✗ MISS |
Q3 2024 | Aug 28, 2024 | $-0.51 | $-0.07 | +86.3% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | — | $-0.26 | — | — |
Q1 2024 | Mar 29, 2024 | $-0.10 | $0.02 | +116.2% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | — | $-0.25 | — | — |
Q3 2023 | Aug 17, 2023 | $-0.26 | $-0.28 | -7.2% | ✗ MISS |
Q2 2023 | May 1, 2023 | — | $-0.56 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.29 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.41 | — | — |
Q3 2022 | Aug 30, 2022 | $-0.16 | $-0.54 | -235.0% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.34 | $-0.44 | -28.3% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-0.54 | — | — |
Q2 2021 | Apr 28, 2021 | — | $0.98 | — | — |
Q1 2021 | Feb 5, 2021 | $-0.09 | $0.01 | +114.9% | ✓ BEAT |
Latest News
NovaBridge Highlights Presentation Of Ragistomig Phase 1 Dose Expansion Data At ESMO-IO
➖ NeutralReported Earlier, NovaBridge Highlights Ragistomig 4-1BB X PD-L1 Bispecific Antibody For Patients Relapsed Or Refractory To Checkpoint Inhibitors
➖ NeutralFrequently Asked Questions about NBP
What is NBP's current stock price?
What is the analyst price target for NBP?
What sector is NovaBridge Biosciences in?
What is NBP's market cap?
Does NBP pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NBP for comparison